Immunovia publ AB (IMMNOV) - Net Assets
Based on the latest financial reports, Immunovia publ AB (IMMNOV) has net assets worth Skr64.73 Million SEK (≈ $6.97 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr88.21 Million ≈ $9.49 Million USD) and total liabilities (Skr23.48 Million ≈ $2.53 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Immunovia publ AB liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr64.73 Million |
| % of Total Assets | 73.39% |
| Annual Growth Rate | 34.86% |
| 5-Year Change | -85.08% |
| 10-Year Change | -76.6% |
| Growth Volatility | 209.43 |
Immunovia publ AB - Net Assets Trend (2012–2025)
This chart illustrates how Immunovia publ AB's net assets have evolved over time, based on quarterly financial data. Also explore how large is Immunovia publ AB's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Immunovia publ AB (2012–2025)
The table below shows the annual net assets of Immunovia publ AB from 2012 to 2025. For live valuation and market cap data, see Immunovia publ AB (IMMNOV) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr64.73 Million ≈ $6.97 Million |
+455.71% |
| 2024-12-31 | Skr11.65 Million ≈ $1.25 Million |
-82.61% |
| 2023-12-31 | Skr66.99 Million ≈ $7.21 Million |
-72.52% |
| 2022-12-31 | Skr243.80 Million ≈ $26.24 Million |
-43.81% |
| 2021-12-31 | Skr433.90 Million ≈ $46.70 Million |
-27.61% |
| 2020-12-31 | Skr599.40 Million ≈ $64.51 Million |
+67.62% |
| 2019-12-31 | Skr357.61 Million ≈ $38.48 Million |
-22.59% |
| 2018-12-31 | Skr461.95 Million ≈ $49.71 Million |
+95.08% |
| 2017-12-31 | Skr236.80 Million ≈ $25.48 Million |
-14.40% |
| 2016-12-31 | Skr276.63 Million ≈ $29.77 Million |
+230.11% |
| 2015-12-31 | Skr83.80 Million ≈ $9.02 Million |
+134.45% |
| 2014-12-31 | Skr35.74 Million ≈ $3.85 Million |
+623.64% |
| 2013-12-31 | Skr4.94 Million ≈ $531.55K |
+272.48% |
| 2012-12-31 | Skr1.33 Million ≈ $142.71K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Immunovia publ AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 128074409500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr20.18 Million | 31.17% |
| Other Comprehensive Income | Skr16.59 Million | 25.63% |
| Other Components | Skr1.31 Billion | 2022.04% |
| Total Equity | Skr64.73 Million | 100.00% |
Immunovia publ AB Competitors by Market Cap
The table below lists competitors of Immunovia publ AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fitters Diversified Bhd
KLSE:9318
|
$14.70 Million |
|
Giga Media Ltd
NASDAQ:GIGM
|
$14.70 Million |
|
Relpol SA
WAR:RLP
|
$14.70 Million |
|
Inbest Prime VII Inmuebles SOCIMI S.A.
MC:YINB7
|
$14.70 Million |
|
Samil Co.Ltd
KQ:032280
|
$14.69 Million |
|
Way 2 Vat Ltd
AU:W2V
|
$14.69 Million |
|
CADOGAN ENERGY SOLUTIONS
F:CPD
|
$14.68 Million |
|
Genmin Ltd
AU:GEN
|
$14.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunovia publ AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,649,000 to 64,735,000, a change of 53,086,000 (455.7%).
- Net loss of 145,915,000 reduced equity.
- New share issuances of 138,022,000 increased equity.
- Other comprehensive income increased equity by 60,725,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-145.91 Million | -225.4% |
| Share Issuances | Skr138.02 Million | +213.21% |
| Other Comprehensive Income | Skr60.73 Million | +93.81% |
| Other Changes | Skr253.00K | +0.39% |
| Total Change | Skr- | 455.71% |
Book Value vs Market Value Analysis
This analysis compares Immunovia publ AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.91x to 1.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.11 | Skr0.20 | x |
| 2013-12-31 | Skr0.40 | Skr0.20 | x |
| 2014-12-31 | Skr2.86 | Skr0.20 | x |
| 2015-12-31 | Skr6.81 | Skr0.20 | x |
| 2016-12-31 | Skr17.13 | Skr0.20 | x |
| 2017-12-31 | Skr12.98 | Skr0.20 | x |
| 2018-12-31 | Skr23.12 | Skr0.20 | x |
| 2019-12-31 | Skr16.96 | Skr0.20 | x |
| 2020-12-31 | Skr26.07 | Skr0.20 | x |
| 2021-12-31 | Skr17.79 | Skr0.20 | x |
| 2022-12-31 | Skr10.00 | Skr0.20 | x |
| 2023-12-31 | Skr1.72 | Skr0.20 | x |
| 2024-12-31 | Skr0.14 | Skr0.20 | x |
| 2025-12-31 | Skr0.19 | Skr0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunovia publ AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -225.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21301.46%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.36x
- Recent ROE (-225.40%) is below the historical average (-116.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -19.52% | -123.99% | 0.07x | 2.26x | Skr-391.51K |
| 2013 | -32.32% | -135.45% | 0.16x | 1.51x | Skr-2.09 Million |
| 2014 | -24.79% | -2466.58% | 0.01x | 1.09x | Skr-12.43 Million |
| 2015 | -8.81% | -3598.41% | 0.00x | 1.09x | Skr-15.76 Million |
| 2016 | -5.32% | -8304.88% | 0.00x | 1.02x | Skr-42.39 Million |
| 2017 | -19.10% | -30364.72% | 0.00x | 1.06x | Skr-68.91 Million |
| 2018 | -18.73% | -26019.22% | 0.00x | 1.03x | Skr-132.73 Million |
| 2019 | -32.02% | -32168.82% | 0.00x | 1.17x | Skr-150.28 Million |
| 2020 | -24.60% | -40732.32% | 0.00x | 1.10x | Skr-207.39 Million |
| 2021 | -36.27% | -18649.05% | 0.00x | 1.14x | Skr-200.79 Million |
| 2022 | -59.49% | -12666.72% | 0.00x | 1.23x | Skr-169.41 Million |
| 2023 | -461.91% | -19646.92% | 0.02x | 1.47x | Skr-316.14 Million |
| 2024 | -657.06% | -8221.37% | 0.03x | 2.84x | Skr-77.71 Million |
| 2025 | -225.40% | -21301.46% | 0.01x | 1.36x | Skr-152.39 Million |
Industry Comparison
This section compares Immunovia publ AB's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $135,027,249
- Average return on equity (ROE) among peers: -20.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunovia publ AB (IMMNOV) | Skr64.73 Million | -19.52% | 0.36x | $14.70 Million |
| AroCell AB (AROC) | $80.41 Million | -20.15% | 0.14x | $13.39 Million |
| Devyser Diagnostics AB (DVYSR) | $431.44 Million | -10.65% | 0.16x | $168.47 Million |
| Prostatype Genomics AB (PROGEN) | $35.91 Million | -43.53% | 0.12x | $4.83 Million |
| SenzaGen AB (SENZA) | $107.79 Million | -25.34% | 0.03x | $17.21 Million |
| Vimian Group AB (VIMIAN) | $19.59 Million | -4.03% | 0.70x | $1.70 Billion |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.